The evolving role of receptors as predictive biomarkers for metastatic breast cancer

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30.
   PubMed Web of Science ®Google Scholar
• Atkinson AJ, Colburn WA, DeGruttola VG, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95.
   PubMed Web of Science ®Google Scholar
• FDA-NIH Biomarker Working Group. BEST (biomarkers, endpoints, and other tools) resource. Food and Drug Administration (FDA) and National Institutes of Health (NIH). Silver Spring and Bethesda, MD; 2017.
   Google Scholar
• Nicolini A, Ferrari P, Duffy MJ. Prognostic and predictive biomarkers in breast cancer: past, present and future. Semin Cancer Biol. 2018;52:56-73.
   PubMed Web of Science ®Google Scholar
• Donegan WL. Tumor-related prognostic factors for breast cancer. CA Cancer J Clin. 1997;47:28–51.
   PubMed Web of Science ®Google Scholar
• Cianfrocca M. Prognostic and predictive factors in early-stage breast cancer. Oncologist. 2004;9:606–616.
   PubMed Web of Science ®Google Scholar
• Győrffy B, Hatzis C, Sanft T, et al. Multigene prognostic tests in breast cancer: past, present, future. Breast Cancer Res. 2015;17:11.
   PubMed Web of Science ®Google Scholar
• Duffy MJ, O’Donovan N, McDermott E, et al. Validated biomarkers: the key to precision treatment in patients with breast cancer. Breast. 2016;29:192–201.
   PubMed Web of Science ®Google Scholar
• Duffy MJ, Harbeck N, Nap M, et al. Clinical use of biomarkers in breast cancer: updated guidelines from the European Group On Tumor Markers (EGTM). Eur J Cancer. 2017;75:284–298.
   PubMed Web of Science ®Google Scholar
• Schwaederle M, Zhao M, Lee JJ, et al. Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trials. J Clin Oncol. 2015;33:3817–3825.
   PubMed Web of Science ®Google Scholar
• Nemere I, Pietras RJ, Blackmore PF. Membrane receptors for steroid hormones: signal transduction and physiological significance. J Cell Biochem. 2003;88:438–445.
   PubMed Web of Science ®Google Scholar
• Marino M, Galluzzo P, Ascenzi P. Estrogen signaling multiple pathways to impact gene transcription. Curr Genomics. 2006;7:497-508.
   PubMed Web of Science ®Google Scholar
• Thomas C, Gustafsson JÅ. The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer. 2011;11:597–608.
   PubMed Web of Science ®Google Scholar
• Björnström L, Sjöberg M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol. 2005;19:833–842.
   PubMed Web of Science ®Google Scholar
• Nicholson RI, Gee JMW. Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer. Br J Cancer. 2000;82:501–513.
   PubMed Web of Science ®Google Scholar
• Arpino G, Wiechmann L, Osborne CK, et al. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev. 2008;29:217–233.
   PubMed Web of Science ®Google Scholar
• Elder K, Dixon JMM, Blackmur JP, et al. Endocrine therapy for cancer. Surgery. 2018;36:134–138.
   Google Scholar
• Clarke R, Tyson JJ, Dixon JM. Endocrine resistance in breast cancer – an overview and update. Mol Cell Endocrinol. 2015;418:220–234.
   PubMed Web of Science ®Google Scholar
• Clarke R, Leonessa F, Welch JN, et al. Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev. 2001;53:25–71.
   PubMed Web of Science ®Google Scholar
• Clarke R, Skaar TC, Bouker KB, et al. Molecular and pharmacological aspects of antiestrogen resistance. J Steroid Biochem Mol Biol. 2001;76:71–84.
   PubMed Web of Science ®Google Scholar
• Carroll JS. Mechanisms of oestrogen receptor (ER) gene regulation in breast cancer. Eur J Endocrinol. 2016;175:R41–9.
   PubMed Web of Science ®Google Scholar
• Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: the second decade. Cell. 1995;83:835–839.
   PubMed Web of Science ®Google Scholar
• Mohammed H, Russell IA, Stark R, et al. Progesterone receptor modulates ERα action in breast cancer. Nature. 2015;523:313–317.
   PubMed Web of Science ®Google Scholar
• Carroll JS, Hickey TE, Tarulli GA, et al. Deciphering the divergent roles of progestogens in breast cancer. Nat Rev Cancer. 2017;17:54–64.
   PubMed Web of Science ®Google Scholar
• Viale G, Regan MM, Maiorano E, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1–98. J Clin Oncol. 2007;25:3846–3852.
   PubMed Web of Science ®Google Scholar
• Olivotto IA, Truong PT, Speers CH, et al. Time to stop progesterone receptor testing in breast cancer management. J Clin Oncol. 2004;22:1769–1770.
   PubMed Web of Science ®Google Scholar
• Ravdin PM, Green S, Dorr TM, et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective southwest oncology group study. J Clin Oncol. 1992;10:1284–1291.
   PubMed Web of Science ®Google Scholar
• Nordenskjöld A, Fohlin H, Fornander T, et al. Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer. Breast Cancer Res Treat. 2016;160:313–322.
   PubMed Web of Science ®Google Scholar
• Stendahl M, Rydén L, Nordenskjöld B, et al. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res. 2006;12:4614–4618.
   PubMed Web of Science ®Google Scholar
• Bardou VJ, Arpino G, Elledge RM, et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003;21:1973–1979.
   PubMed Web of Science ®Google Scholar
• Dowsett M, Houghton J, Iden C, et al. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol. 2006;17:818–826.
   PubMed Web of Science ®Google Scholar
• Grassadonia A, Vici P, Gamucci T, et al. Long-term outcome of breast cancer patients with pathologic N3a lymph node stage. Breast. 2017;32:79–86.
   PubMed Web of Science ®Google Scholar
• Van Belle V, Van Calster B, Brouckaert O, et al. Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham prognostic index up to 5 years after breast cancer diagnosis. J Clin Oncol. 2010;28:4129–4134.
   PubMed Web of Science ®Google Scholar
• Liu S, Chia SK, Mehl E, et al. Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients. Breast Cancer Res Treat. 2010;119:53–61.
   PubMed Web of Science ®Google Scholar
• Salmen J, Neugebauer J, Fasching PA, et al. Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies. Breast Cancer Res Treat. 2014;148:143–151.
   PubMed Web of Science ®Google Scholar
• Fossati R, Confalonieri C, Torri V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol. 1998;16:3439–3460.
   PubMed Web of Science ®Google Scholar
• Mauri D, Pavlidis N, Ioannidis JPA. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005;97:188–194.
   PubMed Web of Science ®Google Scholar
• Creighton CJ, Kent Osborne C, Van De Vijver MJ, et al. Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat. 2009;114:287–299.
   PubMed Web of Science ®Google Scholar
• Brennan M, Lim B. (2015). The Actual Role of Receptors as Cancer Markers, Biochemical and Clinical Aspects: Receptors in Breast Cancer. In: Scatena R. (eds) Advances in Cancer Biomarkers. Advances in Experimental Medicine and Biology, vol 867. Springer, Dordrecht.
   Google Scholar
• Cui X, Schiff R, Arpino G, et al. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol. 2005;23:7721–7735.
   PubMed Web of Science ®Google Scholar
• Finn RS, Dering J, Ginther C, et al. ER+ PR- breast cancer defines a unique subtype of breast cancer that is driven by growth factor signaling and may be more likely to respond to EGFR targeted therapies. J Clin Oncol. 2006;24:514.
   Web of Science ®Google Scholar
• Mcguire WL. Estrogen receptors in human breast cancer. J Clin Invest. 1973;52:73–77.
   PubMed Web of Science ®Google Scholar
• Horowitz K, McGuire W. Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science. 1975;189:726–727.
   PubMed Web of Science ®Google Scholar
• Dodson A, Parry S, Ibrahim M, et al. Abstract P3–08-16: ER, PR and HER2 biomarkers in UK and Irish clinical breast cancer testing: analysis of results from >168,000 patients. Cancer Res. 2018;78:P3–08–16.
   Web of Science ®Google Scholar
• Lovekin C, Ellis IO, Locker A, et al. c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer. 1991;63:439–443.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707–712.
   PubMed Web of Science ®Google Scholar
• Rimawi MF, Schiff R, Osborne CK. Targeting HER2 for the treatment of breast cancer. Annu Rev Med. 2015;66:111–128.
   PubMed Web of Science ®Google Scholar
• Slamon D, Clark G, Wong S, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–182.
   PubMed Web of Science ®Google Scholar
• Thor A. HER2-a discussion of testing approaches in the USA. Ann Oncol. 2001;12(Suppl 1):S101–7.
   PubMedGoogle Scholar
• Furrer D, Sanschagrin F, Jacob S, et al. Advantages and disadvantages of technologies for HER2 testing in breast cancer specimens: table 1. Am J Clin Pathol. 2015;144:686–703.
   PubMed Web of Science ®Google Scholar
• Perez EA, Cortés J, Gonzalez-Angulo AM, et al. HER2 testing: current status and future directions. Cancer Treat Rev. 2014;40:276–284.
   PubMed Web of Science ®Google Scholar
• Roche PC, Suman VJ, Jenkins RB, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst. 2002;94:855–857.
   PubMedGoogle Scholar
• Perez EA, Press MF, Dueck AC, et al. Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005). Breast Cancer Res Treat. 2013;138:99–108.
   PubMed Web of Science ®Google Scholar
• Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing – national surgical adjuvant breast and bowel project experience. J Natl Cancer Inst. 2002;94:852–854.
   PubMed Web of Science ®Google Scholar
• Reddy JC, Reimann JD, Anderson SM, et al. Concordance between central and local laboratory HER2 testing from a community-based clinical study. Clin Breast Cancer. 2006;7:153–157.
   PubMed Web of Science ®Google Scholar
• Perez EA, Suman VJ, Davidson NE, et al. HER2 testing by local, central, and reference laboratories in specimens from the north central cancer treatment group N9831 intergroup adjuvant trial. J Clin Oncol. 2006;24:3032–3038.
   PubMed Web of Science ®Google Scholar
• Vigo S, Mainella A, Sansano M, et al. Correlation between IHC and FISH for HER2/neu assessment in patients with breast cancer. J Clin Oncol. 2008;26:20718.
   Google Scholar
• Zoppoli G, Garuti A, Cirmena G, et al. Her2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer cases. J Transl Med. 2017;15:91.
   PubMed Web of Science ®Google Scholar
• Rakha EA, Pinder SE, Bartlett JMS, et al. Updated UK recommendations for HER2 assessment in breast cancer. J Clin Pathol. 2015;68:93–99.
   PubMed Web of Science ®Google Scholar
• Payandeh M, Sadeghi M, Sadeghi E, et al. Is there any concordance between of IHC with FISH in HER2-positive breast cancer patients? Int J Hematol Stem Cell Res. 2017;11:43–48.
   PubMedGoogle Scholar
• Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. arch. Pathol Lab Med. 2018;142:1364-1382.
   Web of Science ®Google Scholar
• Dawood S, Broglio K, Buzdar AU, et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol. 2010;28:92–98.
   PubMed Web of Science ®Google Scholar
• Chia SK. Neoadjuvant and adjuvant therapy for HER2 positive disease. Am Soc Clin Oncol Educ B. 2015;35:e41–e48.
   Google Scholar
• Eroglu Z, Tagawa T, Somlo G. Human epidermal growth factor receptor family-targeted therapies in the treatment of Her2-overexpressing breast cancer. Oncologist. 2014;19:135–150.
   PubMed Web of Science ®Google Scholar
• Martin M, López-Tarruella S. Emerging therapeutic options for HER2-positive breast cancer. Am Soc Clin Oncol Educ B. 2016;36:e64–e70.
   Google Scholar
• Dent S, Oyan B, Honig A, et al. HER2-targeted therapy in breast cancer: a systematic review of neoadjuvant trials. Cancer Treat Rev. 2013;39:622–631.
   PubMed Web of Science ®Google Scholar
• Loibl S, Gianni L. HER2-positive breast cancer. Lancet. 2017;389:2415–2429.
   PubMed Web of Science ®Google Scholar
• Park HS, Sohn J, Kim SI, et al. Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer. Breast Cancer Res Treat. 2017;163:255–262.
   PubMed Web of Science ®Google Scholar
• Hicks M, Macrae ER, Abdel-Rasoul M, et al. Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trials. Oncologist. 2015;20:337–343.
   PubMed Web of Science ®Google Scholar
• Gianni L, Pienkowski T, Im Y-H, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (neosphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13:25–32.
   PubMed Web of Science ®Google Scholar
• Swain SM, Kim SB, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013;14:461–471.
   PubMed Web of Science ®Google Scholar
• Llombart-Cussac A, Cortés J, Paré L, et al. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. Lancet Oncol. 2017;18:545–554.
   PubMed Web of Science ®Google Scholar
• Larionov AA. Current therapies for human epidermal growth factor receptor 2-positive metastatic breast cancer patients. Front Oncol. 2018;8:89.
   PubMed Web of Science ®Google Scholar
• Figueroa-Magalhães MC, Jelovac D, Connolly R, et al. Treatment of HER2-positive breast cancer. Breast. 2014;23:128–136.
   PubMed Web of Science ®Google Scholar
• Callahan R, Hurvitz S. Human epidermal growth factor receptor-2-positive breast cancer: current management of early, advanced, and recurrent disease. Curr Opin Obstet Gynecol. 2011;23:37–43.
   PubMed Web of Science ®Google Scholar
• Schwab RB, Koehler M, Ali SM, et al. Genomic profiling and treatment of HER2+, ER+, PgR+ “triple positive” breast cancer: a case report and literature review. Cancer Treat Res Commun. 2016;9:27–31.
   Google Scholar
• Orphanos G, Kountourakis P. Targeting the HER2 Receptor in metastatic breast cancer. Hematol Oncol Stem Cell Ther. 2012;5:127–137.
   PubMedGoogle Scholar
• Zardavas D, Irrthum A, Swanton C, et al. Clinical management of breast cancer heterogeneity. Nat Rev Clin Oncol. 2015;12:381–394.
   PubMed Web of Science ®Google Scholar
• Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883–892.
   PubMed Web of Science ®Google Scholar
• Diamantis A, Magiorkinis E, Koutselini H. Fine-needle aspiration (FNA) biopsy: historical aspects. Folia Histochem Cytobiol. 2009;47:191–197.
   PubMed Web of Science ®Google Scholar
• Welch DR. Tumor Heterogeneity–A “contemporary concept” founded on historical insights and predictions. Cancer Res. 2016;76:4–6.
   PubMed Web of Science ®Google Scholar
• Greer LT, Rosman M, Mylander WC, et al. Does breast tumor heterogeneity necessitate further immunohistochemical staining on surgical specimens? J. Am Coll Surg Elsevier. 2013;216:239–251.
   PubMed Web of Science ®Google Scholar
• Petrau C, Clatot F, Cornic M, et al. Reliability of prognostic and predictive factors evaluated by needle core biopsies of large breast invasive tumors. Am J Clin Pathol. 2015;144:555–562.
   PubMed Web of Science ®Google Scholar
• Vance GH, Barry TS, Bloom KJ, et al. Genetic heterogeneity in HER2 testing in breast cancer. Arch Pathol Lab Med. 2009;133:611–612.
   PubMed Web of Science ®Google Scholar
• Seol H, Lee HJ, Choi Y, et al. Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance. Mod Pathol. 2012;25:938–948.
   PubMed Web of Science ®Google Scholar
• Welch HG, Gorski DH, Albertsen PC. Trends in metastatic breast and prostate cancer — Lessons in cancer dynamics. N Engl J Med. 2015;373:1685–1687.
   PubMed Web of Science ®Google Scholar
• Dixon JM. Endocrine resistance in breast cancer. New J Sci. 2014;2014:1–27.
   Google Scholar
• Cobleigh MA, Anderson SJ, Juilan TB, et al. NSABP B-43: a phase III clinical trial to compare trastuzumab (T) given concurrently with radiation therapy (RT) to RT alone for women with HER2+ DCIS resected by lumpectomy (Lx). Jco. 2013;31:Abstract TPS666.
   Web of Science ®Google Scholar
• Rexer BN, Arteaga CL. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit Rev Oncog. 2012;17:1–16.
   PubMedGoogle Scholar
• Sonnenblick A, Pondé N, Piccart M. Metastatic breast cancer: the Odyssey of personalization. Mol Oncol. 2016;10:1147–1159.
   PubMed Web of Science ®Google Scholar
• Ellsworth RE, Blackburn HL, Shriver CD, et al. Molecular heterogeneity in breast cancer: state of the science and implications for patient care. Semin Cell Dev Biol. 2017;64:65–72.
   PubMed Web of Science ®Google Scholar
• Toss A, Palazzo J, Berger A, et al. Clinical-pathological features and treatment modalities associated with recurrence in DCIS and micro-invasive carcinoma: who to treat more and who to treat less. Breast. 2016;29:223–230.
   PubMed Web of Science ®Google Scholar
• Gavilá J, Lopez-Tarruella S, Saura C, et al. SEOM clinical guidelines in metastatic breast cancer 2015. Clin Transl Oncol. 2015;17:946–955.
   PubMed Web of Science ®Google Scholar
• Largillier R, Ferrero JM, Doyen J, et al. Prognostic factors in 1038 women with metastatic breast cancer. Ann Oncol. 2008;19:2012–2019.
   PubMed Web of Science ®Google Scholar
• Cardoso F, Costa A, Norton L, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†. Ann Oncol. 2014;25:1871–1888.
   PubMed Web of Science ®Google Scholar
• Tsimberidou A-M, Wen S, Hong DS, et al. Personalized medicine for patients with advanced cancer in the phase i program at MD anderson: validation and landmark analyses. Clin Cancer Res. 2014;20:4827–4836.
   PubMed Web of Science ®Google Scholar
• Tsimberidou A-M, Iskander NG, Hong DS, et al. Personalized medicine in a phase i clinical trials program: the MD anderson cancer center initiative. Clin Cancer Res. 2012;18:6373–6383.
   PubMed Web of Science ®Google Scholar
• Kaufmann M, Jonat W, Kleeberg U, et al. Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex trial group. J Clin Oncol. 1989;7:1113–1119.
   PubMed Web of Science ®Google Scholar
• Kurebayashi J, Sonoo H, Inaji H, et al. Endocrine therapies for patients with recurrent breast cancer: predictive factors for responses to first- and second-line endocrine therapies. Oncology. 2000;59(Suppl 1):31–37.
   PubMedGoogle Scholar
• Boér K. Fulvestrant in advanced breast cancer: evidence to date and place in therapy. Ther Adv Med Oncol. 2017;9:465–479.
   PubMed Web of Science ®Google Scholar
• Rugo HS, Rumble RB, Macrae E, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American society of clinical oncology guideline. J Clin Oncol. 2016;34:3069–3103.
   PubMed Web of Science ®Google Scholar
• Fabi A, Malaguti P, Vari S, et al. First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces? J. Exp Clin Cancer Res BioMed Central. 2016;104.
   PubMed Web of Science ®Google Scholar
• Yao M, Fu P. Advances in anti-HER2 therapy in metastatic breast cancer. Chinese Clin Oncol. 2018;7:27.
   PubMed Web of Science ®Google Scholar
• Collovà E, Ferzi A, Scandurra G, et al. Efficacy of trastuzumab in unselected patients with HER2-positive metastatic breast cancer: a retrospective analysis. Tumori. 2014.
   PubMed Web of Science ®Google Scholar
• Kuukasjärvi T, Karhu R, Tanner M, et al. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res. 1997;57:1597–1604.
   PubMed Web of Science ®Google Scholar
• Becker TE, Ellsworth RE, Deyarmin B, et al. The genomic heritage of lymph node metastases: implications for clinical management of patients with breast cancer. Ann Surg Oncol. 2008;15:1056–1063.
   PubMedGoogle Scholar
• Nik-Zainal S, Van Loo P, Wedge DC, et al. The life history of 21 breast cancers. Cell. 2012;149:994–1007.
   PubMed Web of Science ®Google Scholar
• Valastyan S, Weinberg RAA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147:275–292.
   PubMed Web of Science ®Google Scholar
• Ng CK, Pemberton HN, Reis-Filho JS. Breast cancer intratumor genetic heterogeneity: causes and implications. Expert Rev Anticancer Ther. 2012;12:1021–1032.
   PubMed Web of Science ®Google Scholar
• Selli C, Dixon JM, Sims AH. Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers. Breast Cancer Res. 2016;18:118.
   PubMed Web of Science ®Google Scholar
• Nik-Zainal S, Davies H, Staaf J, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016;534:47–54.
   PubMed Web of Science ®Google Scholar
• Turner NH, Di Leo A. HER2 discordance between primary and metastatic breast cancer: assessing the clinical impact. Cancer Treat Rev. 2013;39:947–957.
   PubMed Web of Science ®Google Scholar
• Aurilio G, Disalvatore D, Pruneri G, et al. A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. Eur J Cancer. 2014;50:277–289.
   PubMed Web of Science ®Google Scholar
• Van Poznak C, Somerfield MR, Bast RC, et al. Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2015;33:2695–2704.
   PubMed Web of Science ®Google Scholar
• Hompes D, Ruers T. Review: incidence and clinical significance of Bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer. Eur J Surg Oncol. 2011;37:737–746.
   PubMed Web of Science ®Google Scholar
• Robertson EG, Baxter G. Tumour seeding following percutaneous needle biopsy: the real story!. Clin Radiol. 2011;66:1007–1014.
   PubMed Web of Science ®Google Scholar
• Liebens F, Carly B, Cusumano P, et al. Breast cancer seeding associated with core needle biopsies: a systematic review. Maturitas Elsevier. 2009;62:113–123.
   PubMed Web of Science ®Google Scholar
• Diaz LK, Wiley EL, Venta LA. Are malignant cells displaced by large-gauge needle core biopsy of the breast?. Am J Roentgenol. 1999;173:1303–1313.
   PubMed Web of Science ®Google Scholar
• Pearce DA, Arthur LM, Turnbull AK, et al. Tumour sampling method can significantly influence gene expression profiles derived from neoadjuvant window studies. Sci Rep. 2016;6:29434.
   PubMed Web of Science ®Google Scholar
• Do H, Dobrovic A. Sequence artifacts in DNA from formalin-fixed tissues: causes and strategies for minimization. Clin Chem. 2015;61:64–71.
   PubMed Web of Science ®Google Scholar
• Hadd AG, Houghton J, Choudhary A, et al. Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens. J Mol Diagnostics. 2013;15:234–247.
   PubMed Web of Science ®Google Scholar
• Ma CX, Reinert T, Chmielewska I, et al. Mechanisms of aromatase inhibitor resistance. Nat Rev Cancer. 2015;15:261–275.
   PubMed Web of Science ®Google Scholar
• Osborne CKK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62:233–247.
   PubMed Web of Science ®Google Scholar
• Araki K, Miyoshi Y. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer. Breast Cancer. 2018;25:392–401.
   Web of Science ®Google Scholar
• Luque-Cabal M, García-Teijido P, Fernández-Pérez Y, et al. Mechanisms behind the resistance to trastuzumab in HER2-amplified breast cancer and strategies to overcome it. Clin Med Insights Oncol. 2016;10:21–30.
   PubMed Web of Science ®Google Scholar
• Gagliato DDM, Jardim DLF, Marchesi MSP, et al. Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer. Oncotarget. 2016;7:64431–64446.
   PubMedGoogle Scholar
• Sherbet GV. PGR (progesterone receptor). Atlas Genet Cytogenet Oncol Haematol. 2017;21:389-397.
   Google Scholar
• Weis KE, Ekena K, Thomas JA, et al. Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. Mol Endocrinol. 1996;10:1388–1398.
   PubMedGoogle Scholar
• Zhang Q-X-X, Borg A, Wolf DMM, et al. An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res. 1997;57:1244–1249.
   PubMed Web of Science ®Google Scholar
• Jeselsohn R, Yelensky R, Buchwalter G, et al. Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin Cancer Res. 2014;20:1757–1767.
   PubMed Web of Science ®Google Scholar
• Toy W, Shen Y, Won H, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013;45:1439–1445.
   PubMed Web of Science ®Google Scholar
• Toy W, Weir H, Razavi P, et al. Activating ESR1 mutations differentially affect the efficacy of ER antagonists. Cancer Discov. 2017;7:277–287.
   PubMed Web of Science ®Google Scholar
• Li S, Shen D, Shao J, et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep. 2013;4:1116–1130.
   PubMed Web of Science ®Google Scholar
• Robinson DRDR, Wu Y-M, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45:1446–1451.
   PubMed Web of Science ®Google Scholar
• Merenbakh-Lamin K, Ben-Baruch N, Yeheskel A, et al. D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer. Cancer Res. 2013;73:6856–6864.
   PubMed Web of Science ®Google Scholar
• Comprehensive molecular portraits of human breast tumours. The Cancer Genome Atlas Network. Nature. 2012;490:61–70.
   PubMed Web of Science ®Google Scholar
• Fanning SW, Mayne CG, Dharmarajan V, et al. Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation. elife. 2016;5:e12792.
   PubMedGoogle Scholar
• Jeselsohn R. Are we ready to use ESR1 mutations in clinical practice? Breast Care. 2017;12:309–313.
   PubMed Web of Science ®Google Scholar
• Jeselsohn R, Buchwalter G, De Angelis C, et al. ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol. 2015;12:573–583.
   PubMed Web of Science ®Google Scholar
• Beije N, Sieuwerts AM, Kraan J, et al. Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients. Mol Oncol. 2018;12:48–57.
   PubMed Web of Science ®Google Scholar
• Wang P, Bahreini A, Gyanchandani R, et al. Sensitive detection of mono- and polyclonal ESR1 mutations in primary tumors, metastatic lesions, and cell-free DNA of breast cancer patients. Clin Cancer Res. 2016;22:1130–1137.
   PubMed Web of Science ®Google Scholar
• Fribbens C, O’Leary B, Kilburn L, et al. Plasma ESR1 mutations and the treatment of estrogen receptor-Positive advanced breast cancer. J Clin Oncol. 2016;34:2961–2968.
   PubMed Web of Science ®Google Scholar
• Schiavon G, Hrebien S, Garcia-Murillas I, et al. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci Transl Med. 2015;7:313ra182.
   PubMed Web of Science ®Google Scholar
• Chandarlapaty S, Chen D, He W, et al. Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 clinical trial. JAMA Oncol. 2016;2:1310–1315.
   PubMed Web of Science ®Google Scholar
• Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, et al. Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patients. Oncotarget. 2017;8:52142–52155.
   PubMedGoogle Scholar
• Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2010;28:4594–4600.
   PubMed Web of Science ®Google Scholar
• Wardell SE, Ellis MJ, Alley HM, et al. Efficacy of SERD/SERM hybrid-CDK4/6 inhibitor combinations in models of endocrine therapy-resistant breast cancer. Clin Cancer Res. 2015;21:5121–5130.
   PubMed Web of Science ®Google Scholar
• Wardell SE, Nelson ER, Chao CA, et al. Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease. Clin Cancer Res. 2013;19:2420–2431.
   PubMed Web of Science ®Google Scholar
• Pinkerton JVJV, Thomas S. Use of SERMs for treatment in postmenopausal women. J Steroid Biochem Mol Biol. 2014;142:142–154.
   PubMed Web of Science ®Google Scholar
• Garner F, Shomali M, Paquin D, et al. RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models. Anticancer Drugs. 2015;26:948–956.
   PubMed Web of Science ®Google Scholar
• Lai A, Kahraman M, Govek S, et al. Identification of GDC-0810 (ARN-810), an orally bioavailable Selective Estrogen Receptor Degrader (SERD) that demonstrates robust activity in tamoxifen-resistant breast cancer xenografts. J Med Chem. 2015;58:4888–4904.
   PubMed Web of Science ®Google Scholar
• Mayer I, Bardia A, Dickler M, et al. Abstract OT3–2-07: phase I study of ARN-810, a novel selective estrogen receptor degrader, in post-menopausal women with locally advanced or metastatic estrogen receptor positive breast cancer. Cancer Res. 2013;73:OT3–2–07.
   PubMed Web of Science ®Google Scholar
• Bihani T, Patel HK, Arlt H, et al. Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), has antitumor activity in multiple ER+breast cancer patient-derived xenograft models. Clin Cancer Res. 2017;23:4793–4804.
   PubMed Web of Science ®Google Scholar
• Spoerke JM, Gendreau S, Walter K, et al. Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. Nat Commun. 2016;7:11579.
   PubMed Web of Science ®Google Scholar
• Dickler M, Villanueva R, Perez Fidalgo J, et al. Abstract PD5–10: a first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-0927, in postmenopausal women with estrogen receptor positive (ER+) HER2-negative metastatic breast cancer (BC). Cancer Res. 2018;78:PD5–10.
   Web of Science ®Google Scholar
• Bardia A, Kabos P, Elledge R, et al. Evaluation of RAD1901, a novel investigational, selective estrogen receptor degrader (SERD), for the treatment of ER-positive (ER+) advanced breast cancer. J Clin Oncol. 2017;35(suppl):abstr1014.
   Google Scholar
• Wang Y, Lonard DMDM, Yu Y, et al. Bufalin is a potent small-molecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1. Cancer Res. 2014;74:1506–1517.
   PubMed Web of Science ®Google Scholar
• Yan F, Yu Y, Chow D-C, et al. Identification of verrucarin a as a potent and selective steroid receptor coactivator-3 small molecule inhibitor. PLoS One. 2014;9:e95243.
   PubMed Web of Science ®Google Scholar
• Hui R, Cornish AL, McClelland RA, et al. Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer. Clin Cancer Res. 1996;2:923–928.
   PubMed Web of Science ®Google Scholar
• Finn RS, Dering J, Conklin D, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11:R77.
   PubMed Web of Science ®Google Scholar
• Finn RSRS, Crown JPJP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16:25–35.
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phas. Lancet Oncol. 2016;17:425–439.
   PubMed Web of Science ®Google Scholar
• Albertson DG. Gene amplification in cancer. Trends Genet. 2006;22:447–455.
   PubMed Web of Science ®Google Scholar
• Nembrot M, Quintana B, Mordoh J. Estrogen receptor gene amplification is found in some estrogen receptor-positive human breast tumors. Biochem Biophys Res Commun. 1990;166:601–607.
   PubMed Web of Science ®Google Scholar
• Albertson DG. Conflicting evidence on the frequency of ESR1 amplification in breast cancer. Nat Genet. 2008;40:821–822.
   PubMed Web of Science ®Google Scholar
• Holst F. Estrogen receptor alpha gene amplification in breast cancer: 25 years of debate. World J Clin Oncol. 2016;7:160.
   PubMed Web of Science ®Google Scholar
• Holst F, Stahl PRPR, Ruiz C, et al. Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet. 2007;39:655–660.
   PubMed Web of Science ®Google Scholar
• Brown LA, Hoog J, Chin S-F, et al. ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet. 2008;40:806–807.
   PubMedGoogle Scholar
• Reis-Filho JS, Drury S, Lambros MB, et al. ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet. 2008;40:809–810.
   PubMedGoogle Scholar
• Horlings HM, Bergamaschi A, Nordgard SH, et al. ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet. 2008;40:807–808.
   PubMedGoogle Scholar
• Vincent-Salomon A, Raynal V, Lucchesi C, et al. ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet. 2008;40:809.
   PubMedGoogle Scholar
• Adélaïde J, Finetti P, Charafe-Jauffret E, et al. Absence of ESR1 amplification in a series of breast cancers. Int J Cancer. 2008;123:2970–2972.
   PubMed Web of Science ®Google Scholar
• Tomita S, Zhang Z, Nakano M, et al. Estrogen receptor α gene ESR1 amplification may predict endocrine therapy responsiveness in breast cancer patients. Cancer Sci. 2009;100:1012–1017.
   PubMed Web of Science ®Google Scholar
• Tsiambas E, Georgiannos SN, Salemis N, et al. Significance of estrogen receptor 1 (ESR-1) gene imbalances in colon and hepatocellular carcinomas based on tissue microarrays analysis. Med Oncol. 2011;28:934–940.
   PubMed Web of Science ®Google Scholar
• Moelans CBCB, Monsuur HN, de Pinth JH, et al. ESR1 amplification is rare in breast cancer and is associated with high grade and high proliferation: a multiplex ligation-dependent probe amplification study. Anal Cell Pathol. 2010;33:13–18.
   Web of Science ®Google Scholar
• Moelans CB, de Weger RA, Monsuur HN, et al. Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma: a multiplex ligation-dependent probe amplification study. Anal Cell Pathol. 2010;33:165–173.
   Web of Science ®Google Scholar
• Moelans CB, de Weger RA, Monsuur HN, et al. Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes. Mod Pathol. 2010;23:1029–1039.
   PubMed Web of Science ®Google Scholar
• Thomas C, Gustafsson J-Å. Not enough evidence to include ESR1 amplification. Nat Rev Cancer. 2011;11:823.
   PubMed Web of Science ®Google Scholar
• Holst F, Moelans CB, Filipits M, et al. On the evidence for ESR1 amplification in breast cancer. Nat Rev Cancer. 2012;12:149.
   PubMed Web of Science ®Google Scholar
• Albertson DG. ESR1 amplification in breast cancer: controversy resolved? J Pathol. 2012;227:1–3.
   PubMed Web of Science ®Google Scholar
• Ooi A, Inokuchi M, Harada S, et al. Gene amplification of ESR1 in breast cancers-fact or fiction? A fluorescence in situ hybridization and multiplex ligation-dependent probe amplification study. J Pathol. 2012;227:8–16.
   PubMed Web of Science ®Google Scholar
• Holst F, Stahl P, Hellwinkel O, et al. Reply to “ESR1 gene amplification in breast cancer: a common phenomenon?” Nat Genet. 2008;40:810–812.
   Web of Science ®Google Scholar
• Holst F, Singer CF. ESR1-amplification- associated estrogen receptor alpha activity in breast cancer. Trends Endocrinol Metab. 2016;27:751–752.
   PubMed Web of Science ®Google Scholar
• Costello JC, Heiser LM, Georgii E, et al. A community effort to assess and improve drug sensitivity prediction algorithms. Nat Biotechnol. 2014;32:1202–1212.
   PubMed Web of Science ®Google Scholar
• Soysal SD, Kilic IB, Regenbrecht CRA, et al. Status of estrogen receptor 1 (ESR1) gene in mastopathy predicts subsequent development of breast cancer. Breast Cancer Res Treat. 2015;151:709–715.
   PubMed Web of Science ®Google Scholar
• Ma CX, Bose R, Ellis MJ. Prognostic and predictive biomarkers of endocrine responsiveness for estrogen receptor positive breast cancer. In: Stearns V, editor. Nov. biomarkers contin. breast cancer. Cham: Springer; 2016. p. 125–154.
   Google Scholar
• Rice LW, Jazaeri AA, Shupnik MA. Estrogen receptor mRNA splice variants in pre- and postmenopausal human endometrium and endometrial carcinoma. Gynecol Oncol. 1997;65:149–157.
   PubMed Web of Science ®Google Scholar
• Taylor SE, Martin-Hirsch PL, Martin FL. Oestrogen receptor splice variants in the pathogenesis of disease. Cancer Lett. 2010;288:133–148.
   PubMed Web of Science ®Google Scholar
• Poola I, Speirs V. Expression of alternatively spliced estrogen receptor alpha mRNAs is increased in breast cancer tissues. J Steroid Biochem Mol Biol. 2001;78:459–469.
   PubMed Web of Science ®Google Scholar
• Horvath G, Leser G, Helou K, et al. Function of the exon 7 deletion variant estrogen receptor α protein in an estradiol-resistant, tamoxifen-sensitive human endometrial adenocarcinoma grown in nude mice. Gynecol Oncol. 2002;84:271–279.
   PubMed Web of Science ®Google Scholar
• Zhang QX, Borg A, Fuqua SA. An exon 5 deletion variant of the estrogen receptor frequently coexpressed with wild-type estrogen receptor in human breast cancer. Cancer Res. 1993;53:5882–5884.
   PubMed Web of Science ®Google Scholar
• Zhang Q-X, Hilsenbeck SG, Fuqua SAW, et al. Multiple splicing variants of the estrogen receptor are present in individual human breast tumors. J Steroid Biochem Mol Biol. 1996;59:251–260.
   PubMed Web of Science ®Google Scholar
• Lemieux P, Fuqua S. The role of the estrogen receptor in tumor progression. J Steroid Biochem Mol Biol. 1996;56:87–91.
   PubMed Web of Science ®Google Scholar
• Bollig A, Miksicek RJ. An estrogen receptor-α splicing variant mediates both positive and negative effects on gene transcription. Mol Endocrinol. 2000;14:634–649.
   PubMed Web of Science ®Google Scholar
• Daffada AA, Johnston SR, Nicholls J, et al. Detection of wild type and exon 5-deleted splice variant oestrogen receptor (ER) mRNA in ER-positive and -negative breast cancer cell lines by reverse transcription/polymerase chain reaction. J Mol Endocrinol. 1994;13:265–273.
   PubMed Web of Science ®Google Scholar
• Daffada AA, Johnston SR, Smith IE, et al. Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer. Cancer Res. 1995;55:288–293.
   PubMed Web of Science ®Google Scholar
• Fuqua SA, Fitzgerald SD, Chamness GC, et al. Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res. 1991;51:105–109.
   PubMed Web of Science ®Google Scholar
• Chen J-M, Cooper DN, Férec C, et al. Genomic rearrangements in inherited disease and cancer. Semin Cancer Biol. 2010;20:222–233.
   PubMed Web of Science ®Google Scholar
• Stephens PJ, McBride DJ, Lin M-L, et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature. 2009;462:1005–1010.
   PubMed Web of Science ®Google Scholar
• Ewald IP, Ribeiro PLI, Palmero EI, et al. Genomic rearrangements in BRCA1 and BRCA2: a literature review. Genet Mol Biol. 2009;32:437–446.
   PubMed Web of Science ®Google Scholar
• Veeraraghavan J, Tan Y, Cao XX, et al. Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers. Nat Commun. 2014;5:4577.
   PubMed Web of Science ®Google Scholar
• Dunbier AK, Anderson H, Ghazoui Z, et al. ESR1 is co-expressed with closely adjacent uncharacterised genes spanning a breast cancer susceptibility locus at 6q25.1. Horwitz MS editor PLoS Genet. 2011;7:e1001382.
   PubMed Web of Science ®Google Scholar
• Baselga J, Coleman RE, Cortés J, et al. Advances in the management of HER2-positive early breast cancer. Crit Rev Oncol/Hematol. 2017;119:113–122.
   PubMed Web of Science ®Google Scholar
• Fedele P, Ciccarese M, Surico G, et al. An update on first line therapies for metastatic breast cancer. Expert Opin Pharmacother. 2018;19:243–252.
   PubMed Web of Science ®Google Scholar
• Esteva FJ, Guo H, Zhang S, et al. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol. 2010;177:1647–1656.
   PubMed Web of Science ®Google Scholar
• Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007;12:395–402.
   PubMed Web of Science ®Google Scholar
• Kataoka Y, Mukohara T, Shimada H, et al. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann Oncol. 2010;21:255–262.
   PubMed Web of Science ®Google Scholar
• Loibl S, Majewski I, Guarneri V, et al. PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. Ann Oncol. 2016;27:1519–1525.
   PubMed Web of Science ®Google Scholar
• Baselga J, Cortés J, Im SA, et al. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol. 2014;32:3753–3761.
   PubMed Web of Science ®Google Scholar
• Pogue-Geile KL, Song N, Jeong JH, et al. Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. J Clin Oncol. 2015;33:1340–1347.
   PubMed Web of Science ®Google Scholar
• Pohlmann PR, Mayer IA, Mernaugh R. Resistance to trastuzumab in breast cancer. Clin Cancer Res. 2009;15:7479–7491.
   PubMed Web of Science ®Google Scholar
• Tortora G. Mechanisms of resistance to HER2 target therapy. JNCI Monogr. 2011;2011:95–98.
   Google Scholar
• Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol. 2007;18:977–984.
   PubMed Web of Science ®Google Scholar
• Sagara Y, Mallory MA, Wong S, et al. Survival benefit of breast surgery for low-grade ductal carcinoma in situ. JAMA Surg. 2015;150:739.
   PubMed Web of Science ®Google Scholar
• Arribas J, Baselga J, Pedersen K, et al. p95HER2 and breast cancer. Cancer Res. 2011;1515–1519.
   PubMedGoogle Scholar
• Wong ALA, Lee S-C. Mechanisms of resistance to trastuzumab and novel therapeutic strategies in HER2-positive breast cancer. Int J Breast Cancer. 2012;2012:1–13.
   Google Scholar
• Sperinde J, Jin X, Banerjee J, et al. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients. Clin Cancer Res. 2010;16:4226–4235.
   PubMed Web of Science ®Google Scholar
• Bose R, Kavuri SM, Searleman AC, et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 2013;3:224–237.
   PubMed Web of Science ®Google Scholar
• Feldinger K, Kong A. Profile of neratinib and its potential in the treatment of breast cancer. Breast Cancer Dove Med Press. 2015;7:147–162.
   PubMed Web of Science ®Google Scholar
• Hyman D, Piha-Paul S, Saura C, et al. Abstract PD2–08: neratinib + fulvestrant in ERBB2-mutant, HER2–non-amplified, estrogen receptor (ER)-positive, metastatic breast cancer (MBC): preliminary analysis from the phase II SUMMIT trial. Cancer Res. 2017;77:PD2–08.
   Web of Science ®Google Scholar
• Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018;554:189–194.
   PubMed Web of Science ®Google Scholar
• Hanker AB, Brewer MR, Sheehan JH, et al. An acquired HER2 T798I gatekeeper mutation induces resistance to neratinib in a patient with HER2 mutant–Driven breast cancer. Cancer Discov. 2017;7:575–585.
   PubMed Web of Science ®Google Scholar
• Flowers M, Birkey Reffey S, Mertz SA, et al. Obstacles, opportunities and priorities for advancing metastatic breast cancer research. Cancer Res. 2017;77:3386–3390.
   PubMed Web of Science ®Google Scholar
• Crowley E, Di Nicolantonio F, Loupakis F, et al. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013;10:472–484.
   PubMed Web of Science ®Google Scholar
• Pantel K, Alix-Panabières C. Real-time liquid biopsy in cancer patients: fact or fiction? Cancer Res. 2013;73:6384–6388.
   PubMed Web of Science ®Google Scholar
• Wong HY, Park BH. Plasma tumor DNA: on your markers, get set, go!. Ann Transl Med. 2014;2:2.
   PubMedGoogle Scholar
• Forshew T, Murtaza M, Parkinson C, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. 2012;4:136ra68.
   PubMed Web of Science ®Google Scholar
• Grover PK, Cummins AG, Price TJ, et al. Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research. Ann Oncol. 2014;25:1506–1516.
   PubMed Web of Science ®Google Scholar
• Sieuwerts AM, Kraan J, Bolt-De Vries J, et al. Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR. Breast Cancer Res Treat. 2009;118:455–468.
   PubMed Web of Science ®Google Scholar
• Canzoniero JV, Park BH. Use of cell free DNA in breast oncology. Biochim Biophys Acta. 2016;1865:266–274.
   PubMed Web of Science ®Google Scholar
• Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor dna in early- and late-stage human malignancies. sci transl med. 2014;6:224ra24.
   PubMed Web of Science ®Google Scholar
• Dawson S-J, Tsui DWY, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;368:1199–1209.
   PubMed Web of Science ®Google Scholar
• Diaz LA Jr., Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32:579–586.
   PubMed Web of Science ®Google Scholar
• Sefrioui D, Perdrix A, Sarafan-Vasseur N, et al. Short report: monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer. Int J Cancer. 2015;137:2513–2519.
   PubMed Web of Science ®Google Scholar
• Chu D, Paoletti C, Gersch C, et al. ESR1 mutations in circulating plasma tumor dna from metastatic breast cancer patients. Clin Cancer Res. 2016;22:993–999.
   PubMed Web of Science ®Google Scholar
• Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, et al. Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens. Transl Res. 2015;166:540–553.e2.
   PubMed Web of Science ®Google Scholar
• Board RE, Wardley AM, Dixon JM, et al. Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Breast Cancer Res Treat. 2010;120:461–467.
   PubMed Web of Science ®Google Scholar
• Clatot F, Perdrix A, Augusto L, et al. Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor. Oncotarget. 2016;7:74448–74459.
   PubMedGoogle Scholar
• Yanagawa T, Kagara N, Miyake T, et al. Detection of ESR1 mutations in plasma and tumors from metastatic breast cancer patients using next-generation sequencing. Breast Cancer Res Treat. 2017;163:231–240.
   PubMed Web of Science ®Google Scholar
• Newman AMAM, Bratman SVSV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20:548–554.
   PubMed Web of Science ®Google Scholar
• Tucker T, Marra M, Friedman JM. Massively parallel sequencing: the next big thing in genetic medicine. Am J Hum Genet. 2009;85:142–154.
   PubMed Web of Science ®Google Scholar
• Shendure J, Ji H. Next-generation DNA sequencing. Nat Biotechnol. 2008;26:1135–1145.
   PubMed Web of Science ®Google Scholar
• Schmitt MW, Kennedy SR, Salk JJ, et al. Detection of ultra-rare mutations by next-generation sequencing. Proc Natl Acad Sci U S A. 2012;109:14508–14513.
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Kinzler KW. Digital PCR. Proc Natl Acad Sci USA. 1999;96:9236–9241.
   PubMed Web of Science ®Google Scholar
• Huggett JF, Cowen S, Foy CA. Considerations for digital PCR as an accurate molecular diagnostic tool. Clin Chem. 2015;61:79–88.
   PubMed Web of Science ®Google Scholar
• Kinde I, Wu J, Papadopoulos N, et al. Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci USA. 2011;108:9530–9535.
   PubMed Web of Science ®Google Scholar
• Wang T, Liu JH, Zhang J, et al. A multiplex allele-specific real-time PCR assay for screening of ESR1 mutations in metastatic breast cancer. Exp Mol Pathol. 2015;98:152–157.
   PubMed Web of Science ®Google Scholar
• Morlan J, Baker J, Sinicropi D. Mutation detection by real-time PCR: a simple, robust and highly selective method. PLoS One. 2009;4:e4584. Schrijver I, editor.
   PubMed Web of Science ®Google Scholar
• Gelsomino L, Gu G, Rechoum Y, et al. ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling. Breast Cancer Res Treat. 2016;157:253–265.
   PubMed Web of Science ®Google Scholar
• Martin LA, Ribas R, Simigdala N, et al. Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance. Nat Commun. 2017;8:1865.
   PubMed Web of Science ®Google Scholar
• Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, et al. Comparison of ESR1 mutations in tumor tissue and matched plasma samples from metastatic breast cancer patients. Transl Oncol. 2017;10:766–771.
   PubMed Web of Science ®Google Scholar
• Guttery DS, Page K, Hills A, et al. Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer. Clin Chem. 2015;61:974–982.
   PubMed Web of Science ®Google Scholar
• Guan X, Ma F, Liu S, et al. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells. Oncotarget. 2016;7:65993–66002.
   PubMedGoogle Scholar
• Fehm T, Hoffmann O, Aktas B, et al. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res. 2009;11:R59.
   PubMed Web of Science ®Google Scholar
• Schramm A, Friedl T, Huober J, et al. Abstract OT1–02-02: the DETECT study program – Personalized treatment in metastatic breast cancer based on circulating tumor cells. Cancer Res. 2016;76:OT1–02.
   Google Scholar
• Polasik A, Schramm A, Friedl T, et al. Abstract OT3–04-02: DETECT III and IV – Individualized CTC-based therapy of metastatic breast cancer. Cancer Res. 2017;77:OT3-04-02.
   Web of Science ®Google Scholar
• Polasik A, Schramm A, Friedl TWP, et al. The DETECT study concept: individualized therapy of metastatic breast cancer. J Clin Oncol. 2016;34:TPS634.
   Web of Science ®Google Scholar